Literature DB >> 7850012

Abnormal calcitonin basal levels and pentagastrin response in patients with chronic renal failure on maintenance hemodialysis.

P Niccoli1, P Brunet, C Roubicek, F Roux, E Baudin, P J Lejeune, Y Berland, B Conte-Devolx.   

Abstract

Hypercalcitoninemia has been reported in renal failure. Using a specific monomeric calcitonin (CT) immunoassay, we measured CT levels in 154 hemodialyzed patients. The relationship between CT and serum intact parathyroid hormone (PTH), gastrin, alkaline phosphatases, phosphate and calcium was studied. The pentagastrin test was performed in 26 patients exhibiting basal hypercalcitoninemia. Basal CT levels over 5.7 pmol/l (20 ng/l) were found in 25.3% of the patients and values higher than 26 pmol/l (90 ng/l) in 7.8%. Although CT is cleared by hemodialysis, post-dialysis CT levels either were unchanged or increased as compared with pre-dialysis values. This suggests that hypercalcitoninemia is not related to a decreased renal clearance, and that hemodialysis induces a specific regulatory pathway. None of the parameters studied were found to explain high CT levels. Of the patients with hypercalcitoninemia, 11.5% exhibited abnormal CT response to pentagastrin but no relationship between CT and phosphate, calcium and PTH levels was evidenced. Our findings confirm high CT monomer levels in renal failure. As there was no correlation with parameters classically involved in CT regulation, its physiological significance remains unclear. Abnormal CT response to pentagastrin raises the problem of its specificity as a tumoral marker with regard to medullary thyroid carcinoma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7850012     DOI: 10.1530/eje.0.1320075

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  12 in total

1.  Serum calcitonin and endothelial dysfunction in chronic kidney disease: a novel risk factor?

Authors:  Mehmet Kanbay; Mahmut Ilker Yilmaz; Baris Afsar; Mutlu Saglam; Emin Ozgur Akgul; Tuncer Cayci; Kayser Caglar; Hilmi Umut Unal; Mahmut Gok; Abdulgaffar Vural; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2012-03-23       Impact factor: 2.370

2.  A case of spurious hypercalcitoninemia: a cautionary tale on the use of plasma calcitonin assays in the screening of patients with thyroid nodules for neoplasia.

Authors:  G I Uwaifo; A T Remaley; M Stene; J C Reynolds; P M Yen; R H Snider; K L Becker; N J Sarlis
Journal:  J Endocrinol Invest       Date:  2001-05       Impact factor: 4.256

3.  Development and application of a novel sensitive immunometric assay for calcitonin in a large cohort of patients with medullary and differentiated thyroid cancer, thyroid nodules, and autoimmune thyroid diseases.

Authors:  Cléber P Camacho; Susan C Lindsey; Teresa S Kasamatsu; Alberto L Machado; João Roberto M Martins; Rosa Paula M Biscolla; Magnus R Dias da Silva; José Gilberto H Vieira; Rui M B Maciel
Journal:  Eur Thyroid J       Date:  2014-06-18

4.  Association of serum calcitonin with coronary artery disease in individuals with and without chronic kidney disease.

Authors:  Mehmet Kanbay; Myles Wolf; Yusuf Selcoki; Yalcin Solak; Mustafa Ikizek; Sema Uysal; Liviu Segall; Ferah Armutcu; Beyhan Eryonucu; Murat Duranay; David Goldsmith; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2011-12-01       Impact factor: 2.370

5.  Expression of sex steroid hormone receptors in C cell hyperplasia and medullary thyroid carcinoma.

Authors:  Claire Bléchet; Pierre Lecomte; Loïc De Calan; Patrice Beutter; Serge Guyétant
Journal:  Virchows Arch       Date:  2007-02-28       Impact factor: 4.064

6.  Calcitonin testing for detection of medullary thyroid cancer in people with thyroid nodules.

Authors:  Hans Hg Verbeek; Jan Willem B de Groot; Wim J Sluiter; Anneke C Muller Kobold; Edwin R van den Heuvel; John Tm Plukker; Thera P Links
Journal:  Cochrane Database Syst Rev       Date:  2020-03-16

7.  Use of procalcitonin in patients on chronic hemodialysis: procalcitonin is not related with increased serum calcitonin.

Authors:  Ken-Ichi Mori; Mitsuru Noguchi; Yasuhiro Sumino; Fuminori Sato; Hiromitsu Mimata
Journal:  ISRN Urol       Date:  2012-05-20

8.  LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations.

Authors:  G H Daniels; L Hegedüs; S P Marso; M A Nauck; B Zinman; R M Bergenstal; J F E Mann; J Derving Karsbøl; A C Moses; J B Buse; R M Tuttle
Journal:  Diabetes Obes Metab       Date:  2015-02-23       Impact factor: 6.577

Review 9.  Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma.

Authors:  Sergio P A Toledo; Delmar M Lourenço; Marcelo Augusto Santos; Marcos R Tavares; Rodrigo A Toledo; Joya Emilie de Menezes Correia-Deur
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

10.  Twenty years of experience with the preoperative diagnosis of medullary cancer in a moderately iodine-deficient region.

Authors:  Tamas Solymosi; Gyula Lukacs Toth; Dezso Nagy; Istvan Gal
Journal:  Int J Endocrinol       Date:  2013-03-06       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.